1. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Issue 10024 (19th March 2016) Authors: James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman,... Journal: Lancet Issue: Volume 387:Issue 10024(2016) Page Start: 1163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brachytherapy for the urologist: A multidisciplinary team update for 2019. (September 2019) Authors: Teixeira, Helen; Kang, Myungkuk; Lees, Kathryn; Beesley, Sharon; Edwards, Albert; Henderson, Alastair Journal: Journal of clinical urology Issue: Volume 12:Number 5(2019) Page Start: 353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). (10th July 2016) Authors: Andronis, Lazaros; Goranitis, Ilias; Pirrie, Sarah; Pope, Ann; Barton, Darren; Collins, Stuart; Daunton, Adam; McLaren, Duncan; O'Sullivan, Joe M.; Parker, Chris; Porfiri, Emilio; Staffurth, John; Stanley, Andrew; Wylie, James; Beesley, Sharon; Birtle, Alison; Brown, Janet E.; Chakraborti, Prabir... Journal: BJU international Issue: Volume 119:Number 4(2017) Page Start: 522 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Issue 3 (March 2023) Authors: Brown, Janet E; Royle, Kara-Louise; Gregory, Walter; Ralph, Christy; Maraveyas, Anthony; Din, Omar; Eisen, Timothy; Nathan, Paul; Powles, Tom; Griffiths, Richard; Jones, Robert; Vasudev, Naveen; Wheater, Matthew; Hamid, Abdel; Waddell, Tom; McMenemin, Rhona; Patel, Poulam; Larkin, James; Faust, G... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Ten-year supra-network experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. (October 2019) Authors: Njoku, Kelechi; Ager, Michael; Serra, Maria; Beesley, Sharon; Robinson, Angus; Pickering, Lisa; Crellin, Perric; Afshar, Mehran; Vyas, Lona; Eardley, Ian; Kayes, Oliver; Elmamoun, Mamoun; Ayres, Benjamin; Henry, Ann; Watkin, Nick; Tree, Alison Journal: Clinical oncology Issue: Volume 31(2019)Supplement 1 Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗